Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here.
LRT Capital Management LLC raised its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 9.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 5,707 shares of the biotechnology company’s stock after purchasing an additional 502 shares during the quarter. LRT Capital Management LLC’s holdings in Repligen were worth $1,026,000 as of its most […]
LRT Capital Management LLC lifted its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 9.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,707 shares of the biotechnology company’s stock after purchasing an additional 502 shares during the quarter. LRT […]
Repligen Co. (NASDAQ:RGEN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price target […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) and Repligen (NASDAQ:RGEN – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership. Insider & Institutional Ownership 92.6% of Neurocrine Biosciences shares […]